Raloxifene, first approved for preventing postmenopausal osteoporosis in 1997, has been approved for two new indications: reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

Eli Lilly, which markets raloxifene as Evista, announced the approval on Sept. 14. Raloxifene, a selective estrogen receptor modulator (SERM), is the second drug indicated to reduce the risk of breast cancer in women at high risk. Tamoxifen was the first. Raloxifene was approved for treating postmenopausal osteoporosis in 1999.

The Food and Drug Administration's Oncologic Drugs Advisory Committee ...